title: Reduced adenosine release from the aged mammalian heart.
abstract: Adenosine (ADO) released in the heart results in enhanced coronary blood flow and reduced catecholamine release and myocardial responsiveness to adrenergic stimulation (anti-adrenergic action). ADO release from the adrenergic-stimulated aged heart is less than that from the young adult heart. Because adrenergic signaling in the aged heart is impaired, this study was conducted to determine if reduced ADO release from the aged heart results from this reduced adrenergic responsiveness. Hearts of 3-4 months (young adult) and 21-22 months (aged) Fischer-344 rats were perfused with ADO deamination and re-phosphorylation inhibited. Coronary effluent ADO levels were determined. Cellular-free ADO levels with and without sodium acetate (NaAc)-induced mitochondrial AMP synthesis were assessed using formed S-adenosylhomocysteine (SAH) in L-homocysteine thiolactone (L-HC)-treated hearts. The activities of SAH-hydrolase were determined. Aged heart ADO release was 61% less than from young hearts. NaAc augmented young heart ADO release by 104%, while that of aged hearts remained unchanged. SAH synthesis was 51% and 56% lower in the aged heart in the absence and presence of NaAc, respectively, despite an 89% greater SAH hydrolase activity found in the aged hearts. Since synthesized AMP may be diverted to IMP and ultimately inosine by AMP deaminase, inosine release was determined. Aged heart inosine levels in the absence and presence of NaAc were 74% and 59% less than for the young hearts. It is concluded that a reduced mitochondrial AMP synthesis is in part responsible for the attenuation in ADO release from the adrenergic-stimulated aged heart.
authors.affiliation: Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01655, USA. richard.fenton@umassmed.edu
authors.forename: Richard A
authors.initials: RA
authors.lastname: Fenton
authors.forename: James G
authors.initials: JG
authors.lastname: Dobson
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D000241:Adenosine / Q000378:metabolism; D000243:Adenosine Deaminase / Q000378:metabolism*; D058892:Adenosine Deaminase Inhibitors / Q000494:pharmacology; D018674:Adrenergic Antagonists / Q000494:pharmacology; D000375:Aging / Q000378:metabolism / Q000502:physiology*; D000818:Animals; D006321:Heart / Q000187:drug effects / Q000502:physiology*; D006867:Hydrolases / Q000378:metabolism; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology; D010477:Perfusion; D051381:Rats; D011916:Rats, Inbred F344; D012435:S-Adenosylhomocysteine / Q000378:metabolism*; D012965:Sodium Chloride / Q000494:pharmacology; D014372:Tubercidin / Q000494:pharmacology
chemical_list: D058892:Adenosine Deaminase Inhibitors; D018674:Adrenergic Antagonists; D012965:Sodium Chloride; C010192:9-(2-hydroxy-3-nonyl)adenine; D012435:S-Adenosylhomocysteine; D006867:Hydrolases; C463961:homocysteinase; D000243:Adenosine Deaminase; D000225:Adenine; D000241:Adenosine; D014372:Tubercidin